The non-communicable diseases represent the leading cause of mortality worldwide, with cardiovascular disease accounting for approximately 47% of these deaths. Obesity is a important risk factor for cardiovascular disease, requiring more and more new interventions as an adjuvant treatment to combat the global epidemic of obesity. Although well-established benefits of omega 3 polyunsaturated fatty acids (n-3) on cardiovascular health, and promising results in experimental models on the reduction of body fat, little attention has been given to the possible effects of this fatty acid in body composition and glucose in humans. Thus, this study aims to evaluate the impact of n-3 supplementation on body composition, glycemic control and the level of cardiovascular risk in adults. For this purpose, it will be a selected a sample of 100 individuals in the control group (placebo supplementation) and 100 individuals for the intervention group (n-3 supplementation) between 30 and 74 years with cardiovascular risk stratified according to the Framingham risk score. This population will be submitted to a protocol for a clinical, randomized, controlled, double blind study following by 2 months. Anthropometric evaluation will be done through the measurement of body mass, height, waist circumference and percentage of lean mass and body fat. The determination of plasma glucose will be through a commercial kit, enzymatic and colorimetric and the detection of insulin will be through the technique of radioimmunoassay. Insulin resistance will be calculated by HOMA-IR. All statistical tests will be carried out with the aid of the Statistical Package for the Social Sciences ® with the value of significance of p <0.05.
News published in Agência FAPESP Newsletter about the scholarship: